Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | QoLATI/DAHANCA34: QoL after TORS vs IMRT in early-stage oropharyngeal cancer

Hani Channir • 25 Oct 2026
ESMO 2026
Head and Neck Cancer
QoLATI/DAHANCA34

Hani Channir, MD, PhD, Rigshospitalet, Copenhagen, Denmark, discusses results from the randomized Phase II QoLATI/DAHANCA34 trial (NCT04124198), which compared transoral robotic surgery (TORS) with (chemo)radiotherapy in early-stage oropharyngeal squamous cell carcinoma. TORS-based treatment was associated with better swallowing-related quality of life (QoL) at 12 months, although the difference did not reach the prespecified threshold for clinical relevance. Objective swallowing, survival and disease control were comparable, supporting both treatments as options for selected patients, guided by patient preferences. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Hani Channir

Balancing toxicity and long-term QoL in HPV-positive oropharyngeal cancer
1:04
Balancing toxicity and long-term QoL in HPV-positive oropharyngeal cancer
Hani Channir • 25 Oct 2026

Related Videos

AI-assisted audit of guideline adherence in head and neck cancer
1:12
AI-assisted audit of guideline adherence in head and neck cancer
Davide Smussi • 24 Oct 2026
Treatment deviations and their impact on outcomes in head and neck cancer
1:14
Treatment deviations and their impact on outcomes in head and neck cancer
Davide Smussi • 24 Oct 2026
Using artificial intelligence to assess adherence to oncology guidelines
0:52
Using artificial intelligence to assess adherence to oncology guidelines
Davide Smussi • 24 Oct 2026
Balancing toxicity and long-term QoL in HPV-positive oropharyngeal cancer
1:04
Balancing toxicity and long-term QoL in HPV-positive oropharyngeal cancer
Hani Channir • 25 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals